Cancer Genetics (NASDAQ:CGIX – Get Free Report) is one of 49 public companies in the “Medical Laboratories” industry, but how does it contrast to its peers? We will compare Cancer Genetics to similar companies based on the strength of its valuation, earnings, analyst recommendations, risk, profitability, institutional ownership and dividends.
Risk & Volatility
Cancer Genetics has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500. Comparatively, Cancer Genetics’ peers have a beta of 1.00, meaning that their average share price is 0% less volatile than the S&P 500.
This table compares Cancer Genetics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cancer Genetics Competitors||-1,439.22%||-368.95%||-41.75%|
Institutional & Insider Ownership
Valuation and Earnings
This table compares Cancer Genetics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cancer Genetics||$6.33 million||N/A||-0.08|
|Cancer Genetics Competitors||$712.49 million||-$139.13 million||-3.32|
Cancer Genetics’ peers have higher revenue, but lower earnings than Cancer Genetics. Cancer Genetics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings for Cancer Genetics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cancer Genetics Competitors||244||908||1851||29||2.55|
As a group, “Medical Laboratories” companies have a potential upside of 41.47%. Given Cancer Genetics’ peers higher possible upside, analysts plainly believe Cancer Genetics has less favorable growth aspects than its peers.
Cancer Genetics beats its peers on 5 of the 9 factors compared.
About Cancer Genetics
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.